Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Pharmacological treatment in early rehabilitation after ischemic stroke].
Pigretti SG, Isaac C, Cea C, Esnaola MM, Riveros M, Tejada Jacob V, Weinberg M, Posadas Martinez ML, Cirelli D, Burgos MA, Zimerman M, Romano M. Pigretti SG, et al. Among authors: esnaola mm. Medicina (B Aires). 2023 Aug;83 Suppl 3:1-40. Medicina (B Aires). 2023. PMID: 37624681 Free article. Review. Spanish.
Cerebral venous thrombosis in Argentina: clinical presentation, predisposing factors, outcomes and  literature review.
Alet M, Ciardi C, Alemán A, Bandeo L, Bonardo P, Cea C, Cirio J, Cossio J, Cuculic M, Esnaola MM, García-Pérez F, Giner F, Gómez-Schneider M, Isaac C, Lepera S, Martínez C, Martínez-Lorenzín R, Montes M, Orzuza G, Persi G, Povedano G, Pujol-Lereis V, Quiroga-Narváez J, Romano M, Sabio R, Viglione J, Zurrú MC, Saposnik G; Argentinian Stroke and Cerebrovascular Diseases Study Group - Argentine Neurological Society. Alet M, et al. Among authors: esnaola mm. J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105145. doi: 10.1016/j.jstrokecerebrovasdis.2020.105145. Epub 2020 Jul 28. J Stroke Cerebrovasc Dis. 2020. PMID: 32912503 Review.
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators. Hart RG, et al. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766772 Free article. Clinical Trial.
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Bousser MG, et al. Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Cerebrovasc Dis. 2009. PMID: 19372653 Free article. Clinical Trial.